Bright Uro, an Aliso Viejo, CA-Based medical device company which aims to transform care of lower urinary tract symptoms (LUTS), raised $6m in Seed funding and grant.
The USD4m round was led by Academy Investor Network, Fred Moll, and and several other angel investors. Bright Uro was also awarded a $2m Phase II SBIR grant from the National Institutes of Health (NIH).
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Derek Herrera, Bright Uro is advancing the investigational Glean Urodynamics System, which is designed to enable wireless, catheter-free urodynamics monitoring, with the ultimate goal of improving patient comfort and clinical outcomes.
The Glean system consists of an insertion tool, a Bluetooth®-enabled pressure sensor in a flexible silicone tube, a software app for use by clinicians and patients, and a uroflowmeter to sense volume and flow.
Bright Uro has obtained exclusivity to the catheter-free method used with the Glean system through a licensing agreement with Cleveland Clinic. This catheter-free design of Glean may enable physicians to gather more ambulatory data with greater physiologic accuracy than the standard of care for urodynamics.
The company has obtained an exclusive licensing agreement from Cleveland Clinic for technology Cleveland Clinic developed in collaboration with the Department of Veterans Affairs, Case Western Reserve University, and Parker Hannifin Corporation, which Bright Uro will use in its investigational Glean Urodynamics System.
FinSMEs
13/06/2022